11.05.2012 - The European Parliament has adopted a non-binding resolution to exempt conventionally-bred plants or animals from patents.
Strasbourg – Although these patents are an important tool for the transfer of technology, the Parliament fears that "excessively broad patent protection can hamper innovation and progress and become detrimental to small and medium breeders by blocking access to animal and plant genetic resources". Therefore, the Parliament called on the European Patent Office to exclude products derived from conventional breeding, such as anti-carcinogenic broccoli or high-yield dairy cows, and all conventional breeding methods from patenting. It also wants the Commission and the Member States to ensure that the EU continues to exempt breeders from its patent law on plant and animal breeding. The non-legislative resolution was adopted by 354 votes to 192, with 22 abstentions.
“This is a huge success for all farmers, breeders and consumers who are concerned about the monopolisation of our food resources,” says Ruth Tippe from the coalition “No Patents On Seeds!“. Despite this, industry experts warn, that the motion might hamper the development of genetically modified crops or animals. The European Parliament therefore asked the European Commission to report “on the development and implications of patent law in the field of biotechnology and genetic engineering“ and to examine the impact of the patenting of breeding methods on the breeding and food industry.
The relevant European patent law dates from 1998. De jure it is impossible to receive patent protection for conventionally bred or genetically modified plant and animal varieties. Environmental Groups such as No Patents On Seeds claim that there is a loophole however: In the past, the European Patent Office protected gm-modified crops on the grounds that only the breeding process could not be patented, but the product regardless.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more